NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

Amneal Pharmaceuticals logo
$21.88 +0.76 (+3.60%)
Closing price 04:00 PM Eastern
Extended Trading
$21.63 -0.25 (-1.16%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Advanced

Key Stats

Today's Range
$21.07
▼
$22.13
50-Day Range
$16.65
▼
$21.88
52-Week Range
$11.45
▼
$22.13
Volume
2.01 million shs
Average Volume
3.85 million shs
Market Capitalization
$7.62 billion
P/E Ratio
22.23
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Moderate Buy

Company Overview

Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology.

The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.

Founded in 2002 by brothers Chirag and Chintu Patel, Amneal became a larger pharmaceutical company following its 2018 combination with Impax Laboratories. It is headquartered in Bridgewater, New Jersey.

AI Generated. May Contain Errors.

Amneal Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

AMRX MarketRank™: 
3.815592203895 of 5 stars

Amneal Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 414th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amneal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Amneal Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Amneal Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Amneal Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amneal Pharmaceuticals are expected to grow by 15.31% in the coming year, from $0.98 to $1.13 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amneal Pharmaceuticals is 22.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.49.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amneal Pharmaceuticals is 22.23, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.48.

  • Price to Earnings Growth Ratio

    Amneal Pharmaceuticals has a PEG Ratio of 2.40. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Amneal Pharmaceuticals has a P/B Ratio of 14.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.31% of the float of Amneal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 2.79, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Amneal Pharmaceuticals has recently decreased by 19.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Amneal Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Amneal Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Amneal Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Amneal Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for AMRX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amneal Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.30% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    31.82% of the stock of Amneal Pharmaceuticals is held by institutions.

  • Read more about Amneal Pharmaceuticals' insider trading history.
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMRX Stock News Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Headlines

AMRX Stock Analysis - Frequently Asked Questions

Amneal Pharmaceuticals' stock was trading at $12.60 on January 1st, 2026. Since then, AMRX shares have increased by 73.7% and is now trading at $21.88.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) posted its earnings results on Tuesday, November, 3rd. The company reported $0.26 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.03. The firm had revenue of $862.68 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.17% and a trailing twelve-month return on equity of 283.50%.
Read the conference call transcript
.

Top institutional investors of Amneal Pharmaceuticals include State Street Corp (2.34%), Allspring Global Investments Holdings LLC (1.20%), Goldman Sachs Group Inc. (0.81%) and Nantahala Capital Management LLC (0.66%). Insiders that own company stock include Tushar Bhikhubhai Patel, Gautam Patel, Ted C Nark, Nikita Shah, John Kiely, Andrew S Boyer, Deborah M Autor and Jason B Daly.
View institutional ownership trends
.

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amneal Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Tesla (TSLA), NIO (NIO), Palantir Technologies (PLTR) and Pfizer (PFE).

Company Calendar

Last Earnings
11/03/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AMRX
Previous Symbol
NASDAQ:AMRX
CIK
1723128
Employees
8,500
Year Founded
2002

Price Target and Rating

High Price Target
$27.00
Low Price Target
$17.00
Potential Upside/Downside
+5.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.42
Trailing P/E Ratio
22.23
Forward P/E Ratio
19.36
P/E Growth
2.4
Net Income
$72.06 million
Net Margins
4.17%
Pretax Margin
6.93%
Return on Equity
283.50%
Return on Assets
7.79%

Debt

Debt-to-Equity Ratio
5.61
Current Ratio
1.87
Quick Ratio
1.24

Sales & Book Value

Annual Sales
$3.02 billion
Price / Sales
2.53
Cash Flow
$1.62 per share
Price / Cash Flow
13.52
Book Value
$1.52 per share
Price / Book
14.39

Miscellaneous

Outstanding Shares
348,410,000
Free Float
288,138,000
Market Cap
$7.62 billion
Optionable
Optionable
Beta
1.24

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:AMRX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners